Cite
HARVARD Citation
Brose, M. et al. (2022). Cabozantinib for previously treated radioiodine‐refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC‐311 trial. Cancer. 128 (24), pp. 4203-4212. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Brose, M. et al. (2022). Cabozantinib for previously treated radioiodine‐refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC‐311 trial. Cancer. 128 (24), pp. 4203-4212. [Online].